Telix Pharmaceuticals Ltd. is an Australian-based pharmaceutical company specializing in developing and distributing molecularly-targeted radiation therapy for prostate, renal, and brain cancer treatment. With a medium risk ESG score of 26.4, the company operates in Australia, the United States, Belgium, and Japan. Its operations include commercial sales of Illuccix® and other products, as well as the development of radiopharmaceutical products for future commercialization.